Luye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan

MT Newswires Live

04/01

Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong bourse.

The product named Rivaluen LA Patch 25.92 mg/51.84 mg is designed to suppress the progression of dementia in mild to moderate Alzheimer's disease. The approval follows successful Phase III trials in Japan.

Luye Pharma has partnered with Japanese generics manufacturer Towa Pharmaceutical (TYO:4553) for commercialization.

Luye Pharma's shares were 2% higher in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2524156338"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524156338\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524156338?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-01 15:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524156338","market":"us","top_or_hot":-1,"title":"Luye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan","media":"MT Newswires Live","content":"<html><body><p> Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong bourse.</p><p>The product named Rivaluen LA Patch 25.92 mg/51.84 mg is designed to suppress the progression of dementia in mild to moderate Alzheimer's disease. The approval follows successful Phase III trials in Japan.</p><p>Luye Pharma has partnered with Japanese generics manufacturer Towa Pharmaceutical (TYO:4553) for commercialization.</p><p>Luye Pharma's shares were 2% higher in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-01 15:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong bourse.</p><p>The product named Rivaluen LA Patch 25.92 mg/51.84 mg is designed to suppress the progression of dementia in mild to moderate Alzheimer's disease. The approval follows successful Phase III trials in Japan.</p><p>Luye Pharma has partnered with Japanese generics manufacturer Towa Pharmaceutical (TYO:4553) for commercialization.</p><p>Luye Pharma's shares were 2% higher in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524156338","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524156338","pubTimestamp":1743490909,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1583":"高瓴概念","BK1606":"中医药概念","02186":"绿叶制药"},"translate_title":"绿叶制药集团卡巴拉汀贴剂在日本获批用于阿尔茨海默病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":0.9},"content_text":"Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong bourse.The product named Rivaluen LA Patch 25.92 mg/51.84 mg is designed to suppress the progression of dementia in mild to moderate Alzheimer's disease. The approval follows successful Phase III trials in Japan.Luye Pharma has partnered with Japanese generics manufacturer Towa Pharmaceutical (TYO:4553) for commercialization.Luye Pharma's shares were 2% higher in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}